Craig H. Moskowitz, MD

Articles by Craig H. Moskowitz, MD

Combining ctDNA and modern imaging with novel therapeutics may help determine subsets of patients who are eligible to receive reduced treatment courses.

How Can the Field Move Forward to Better Manage Lymphoma Subtypes?

April 12th 2026

Combining ctDNA and modern imaging with novel therapeutics may help determine subsets of patients who are eligible to receive reduced treatment courses.

Getting to Transplant Remains Goal in Relapsed/Refractory Hodgkin Lymphoma

ByCraig H. Moskowitz, MD

December 2nd 2016

As part of our coverage of the ASH Annual Meeting, we are discussing novel agents and strategies for relapsed/refractory Hodgkin lymphoma.

Latest Updated Articles

Autologous Stem Cell Transplantation is Having a “Slow Death” in Lymphoma
April 11th 2026
How Can the Field Move Forward to Better Manage Lymphoma Subtypes?
April 12th 2026
$Getting to Transplant Remains Goal in Relapsed/Refractory Hodgkin Lymphoma$
Getting to Transplant Remains Goal in Relapsed/Refractory Hodgkin Lymphoma
December 2nd 2016

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)